8-K/A: Tivic Health Acquires Scorpius Assets Amid Delisting & Debt Defaults

Tivic Health Systems, Inc. has acquired substantially all assets of Scorpius Holdings, Inc. for $16.25 million in cash, following Scorpius's default on secured debt and subsequent delisting from NYSE American.

Summary

• Tivic Health Systems, Inc. acquired substantially all assets of Scorpius Holdings, Inc. for $16.25 million in cash on December 10, 2025, through a foreclosure sale initiated by the collateral agent.
• Scorpius experienced severe financial distress, reporting an accumulated deficit of $287.2 million as of December 31, 2024, and a net loss of $34.3 million for the year ended December 31, 2024.
• Scorpius's auditors and management expressed 'substantial doubt' about its ability to continue as a going concern due to recurring losses and negative cash flows.
• Scorpius defaulted on its December 2024 Secured Convertible Notes and other non-convertible promissory notes, which led to the foreclosure sale of its assets.
• Prior to the asset sale, Scorpius's common stock was suspended from trading and delisted from the NYSE American on April 21, 2025, due to a low selling price and failure to timely file its Annual Report on Form 10-K.
• Scorpius's revenue decreased to $6.24 million in 2024 from $6.99 million in 2023, with a significant customer migrating to a larger CDMO during 2024.
• Scorpius incurred substantial losses from lease assignments and terminations in 2025, totaling $5.73 million for the nine months ended September 30, 2025.
• Tivic Health issued a senior secured convertible note of $16.25 million at 5% annual interest to 3i, LP, the collateral agent, as part of the acquisition.
• Post-acquisition, Scorpius has 'no or nominal operations and no or nominal assets' and does not anticipate generating revenue without a strategic transaction, such as a reverse merger or asset acquisition.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development for Scorpius Holdings, culminating in asset liquidation and delisting due to severe financial distress and debt defaults. For Tivic Health, it represents a strategic acquisition of assets at a distressed price, but also involves taking on new debt and the challenge of integrating a failed operation.

Positives

• Tivic Health acquired key assets, including facilities, equipment, inventory, and intellectual property, related to Scorpius's CDMO business for $16.25 million, potentially at a distressed valuation.
• The acquisition allows Tivic Health to bring manufacturing and related services for its late-stage TLR5 agonist, Entolimod, in-house, enhancing operational control.
• Tivic Health intends to expand its business operations to provide CDMO services to other clients, leveraging the acquired infrastructure and capabilities.

Negatives

• Scorpius Holdings, Inc. has ceased to have significant operations or assets following the foreclosure sale, indicating a complete business failure.
• Scorpius had an accumulated deficit of $287.2 million as of December 31, 2024, and a net loss of $34.3 million for the year, demonstrating persistent unprofitability.
• Scorpius's auditors and management expressed 'substantial doubt' about its ability to continue as a going concern.
• Scorpius defaulted on multiple debt instruments, including $13.39 million in December 2024 Secured Convertible Notes, leading to asset liquidation.
• Scorpius's common stock was delisted from the NYSE American due to low selling price and failure to file its annual report, severely impacting shareholder value.
• Scorpius's revenue declined from $6.99 million in 2023 to $6.24 million in 2024, and further to $0.67 million for the nine months ended September 30, 2025, reflecting a significant business downturn.
• A significant CDMO customer migrated from Scorpius to a larger competitor in 2024, highlighting competitive challenges and customer retention issues.
• Scorpius incurred substantial losses from lease assignments and terminations in 2025, totaling $5.73 million.
• After the foreclosure sale, Scorpius still has $14.95 million in debt and related obligations outstanding, indicating that not all creditors were fully satisfied.
• Tivic Health assumed $16.25 million in new convertible debt as part of the acquisition, adding to its financial obligations.

Risks

• Scorpius's going concern uncertainty due to recurring losses, lack of significant revenue, and negative cash flows.
• Scorpius's inability to obtain substantial additional funding on acceptable terms, which could force delays, reductions, or elimination of its programs and services.
• Dependence on third-party suppliers for key materials and services, posing risks of delays or cancellations if suppliers fail to deliver or are non-compliant with regulations.
• Scorpius's small customer base with mostly short-term contracts and vulnerability to customer migration, as evidenced by a significant customer moving to a larger CDMO.
• Uncertainty of market acceptance for Scorpius's service offerings and intense market competition from similar and larger CDMO companies.
• Dependence on key individuals, such as Jeffrey Wolf, whose continued role was a condition in debt agreements.
• The risk for Scorpius of needing to file for bankruptcy, liquidate, or reorganize if unable to find financing or undertake a strategic alternative post-foreclosure.
• For Tivic, the integration risk associated with acquiring and operationalizing the CDMO assets from a financially distressed entity.
• For Tivic, the financial risk associated with the $16.25 million in new convertible debt incurred for the acquisition.

Future Outlook

Scorpius management stated that it expects to incur significant expenses and continued losses for the foreseeable future, particularly as it ramps up biomanufacturing operations. It will need substantial additional funding and intends to consider multiple alternatives, including equity and debt financings, partnerships, and grants. Post-foreclosure sale, Scorpius has no or nominal operations and assets and does not anticipate generating revenue unless a strategic transaction such as a reverse merger or asset acquisition is consummated, with no assurance of success. Tivic Health intends to expand its business operations to provide CDMO services to other clients in the future, leveraging the acquired assets.

Management Comments

• "Management has determined that there is substantial doubt about the Company's ability to continue as a going concern within one year after the consolidated financial statements are issued."
• "The Company expects to incur significant expenses and continued losses from operations for the foreseeable future."
• "The Company will need to obtain substantial additional funding in connection with its planned operations."
• "If the Company is unable to raise capital when needed or on attractive terms, it will be forced to delay, reduce or eliminate its research and development programs, any future commercialization efforts or the manufacturing services it plans to provide."
• "Management does not expect to generate revenue unless and until the Company consummates a strategic transaction such as a reverse merger or asset acquisition. However, there is no assurance that the Company will be able to find a merger candidate or funding to acquire other assets."
• "If the Company is unable to find financing or undertake a strategic alternative, it may need to file for bankruptcy, liquidate, reorganize, or a combination of the foregoing."

Industry Context

StockSavvy.ai notes that the acquisition of Scorpius's CDMO assets by Tivic Health Systems, Inc. highlights the ongoing consolidation and strategic realignments within the biotechnology and biopharmaceutical contract development and manufacturing organization (CDMO) sector. The distress and eventual asset sale of Scorpius underscore the intense capital requirements and competitive pressures faced by smaller CDMOs, especially those with limited customer bases and recurring losses. For Tivic, this move represents a vertical integration strategy, bringing critical manufacturing capabilities in-house for its own drug development pipeline (e.g., Entolimod) and potentially expanding its service offerings to capitalize on the growing demand for outsourced biomanufacturing, a trend driven by increasing R&D pipelines and specialized manufacturing needs across the broader industry.

Comparison to Industry Standards

• Scorpius's financial performance, characterized by recurring losses and negative cash flows, falls significantly below industry standards for sustainable CDMO operations. For example, larger, established CDMOs like Lonza Group or Catalent, Inc. typically demonstrate consistent revenue growth, positive operating margins, and robust cash generation, reflecting strong customer pipelines and efficient operations.
• The decline in Scorpius's revenue from $6.99 million in 2023 to $6.24 million in 2024, coupled with a significant customer migrating to a larger CDMO, indicates a failure to retain key contracts and compete effectively against industry leaders who offer broader capabilities and greater financial stability.
• The delisting from NYSE American due to low stock price and failure to file reports is a severe deviation from public company governance and financial health standards, contrasting sharply with the compliance and transparency expected from publicly traded peers.
• Tivic's acquisition of these distressed assets at a foreclosure sale price of $16.25 million, while incurring new debt, suggests a strategic opportunity to acquire infrastructure below market value, potentially comparable to how larger players might acquire smaller, struggling firms to expand capacity or technology, but with the added risk of integrating a previously distressed operation.

Management Changes

Corporate Governance

Legal Proceedings

• NYSE Regulation issued a notice of non-compliance and subsequently suspended trading and commenced delisting proceedings against Scorpius due to failure to file its Annual Report on Form 10-K and low selling price.
• The foreclosure sale of Scorpius's assets on November 24, 2025, was a legal proceeding initiated by the collateral agent under the Uniform Commercial Code (Article 9) due to debt defaults.

Related Party Transactions

• Scorpius completed the sale of Elusys Therapeutics, Inc. to Elusys Holdings, a company controlled by Scorpius's Chairman, CEO, and President, Jeffrey Wolf, for approximately $2.5 million in December 2023.
• Scorpius issued a $2.25 million convertible promissory note (Original Elusys Convertible Note, later Restated) to Elusys Holdings in January 2024.
• Scorpius issued a $750,000 non-convertible promissory note to Elusys Holdings in May 2024, which was later cancelled in exchange for an amendment to the Divestiture Agreement.
• Scorpius entered into a Shared Services Agreement with Elusys Holdings, generating fees of $191,586 in 2024.
• The December 2024 Secured Convertible Notes included an event of default clause tied to Jeffrey Wolf's continued role as CEO.
• Multiple non-convertible promissory notes issued in 2025 to an institutional investor had a premium recognized as a component of equity 'due to the related party nature of the transactions'.
• A Second Amendment to the Divestiture Agreement with Elusys Holdings on March 12, 2025, eliminated a $2.5 million payment in exchange for $550,000 cash.

Stakeholder Impact

• **Shareholders (Scorpius)**: Experienced significant negative impact, including delisting, substantial dilution, and likely near-total loss of investment due to the company's effective cessation of operations.
• **Shareholders (Tivic)**: Face potential long-term benefits from acquiring distressed assets at a favorable price, but also immediate impact from issuing new convertible debt and the inherent challenges of integrating a failed business.
• **Creditors (Scorpius)**: Secured creditors partially recovered their investment through the foreclosure sale, but a significant portion of debt ($14.95 million) remains outstanding, indicating potential losses for both secured and unsecured creditors.
• **Employees (Scorpius)**: Faced significant uncertainty and likely job losses due to the cessation of operations and asset sale.
• **Customers (Scorpius)**: Experienced disruption of services as the CDMO business was acquired by Tivic, following a trend of a key customer migrating to a larger CDMO in 2024.

Next Steps

• Scorpius management intends to continue discovery efforts of its subsidiary, Skunkworx, if it has sufficient resources.
• Scorpius management plans to consider multiple alternatives to meet capital needs, including additional equity/debt financings, partnerships, and grants.
• Scorpius management will need to generate significant revenues to achieve profitability, which is uncertain given its current state.
• Scorpius management may need to file for bankruptcy, liquidate, or reorganize if unable to find financing or undertake a strategic alternative.
• Tivic Health intends to expand its business operations to provide CDMO services to other clients in the future, leveraging the acquired assets.
• Tivic Health will need to integrate the acquired assets and operations into its existing business.

Key Dates

Recommendation

For Scorpius Holdings, Inc., the filing details a complete financial collapse, including recurring losses, debt defaults, asset foreclosure, and delisting from NYSE American. The company has ceased to have significant operations or assets and faces potential bankruptcy or liquidation. This situation represents a near-total loss for existing shareholders and warrants a strong sell recommendation. For Tivic Health Systems, Inc., while the acquisition of assets is strategic, it comes with new debt and the inherent risks of integrating a distressed business, making a cautious approach advisable.

Keywords

CDMO, Biomanufacturing, Asset Acquisition, Foreclosure Sale, Going Concern, Debt Default, Delisting, SEC Filing, Financial Distress, Tivic Health Systems, Scorpius Holdings, Convertible Notes, Biotechnology, Pharmaceutical Industry